These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24141807)

  • 41. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
    Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brachytherapy for prostate cancer: is the pretreatment prostate volume important?
    Meyer JP; Bell CR; Elwell C; Kunkler RB
    BJU Int; 2008 Dec; 102(11):1585-8. PubMed ID: 18990138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review.
    Zuber S; Weiß S; Baaske D; Schöpe M; Stevens S; Bodis S; Zwahlen DR
    Radiat Oncol; 2015 Feb; 10():49. PubMed ID: 25880809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rectal function following prostate brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy.
    Teishima J; Iwamoto H; Miyamoto K; Shoji K; Masumoto H; Inoue S; Kobayashi K; Kajiwara M; Matsubara A
    Int J Urol; 2012 Dec; 19(12):1083-9. PubMed ID: 22852805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?
    Keyes M; Schellenberg D; Moravan V; McKenzie M; Agranovich A; Pickles T; Wu J; Liu M; Bucci J; Morris WJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):825-34. PubMed ID: 16458775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy.
    Tsui G; Gillan C; Pond G; Catton C; Crook J
    Cancer J; 2005; 11(2):122-32. PubMed ID: 15969987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of late toxicity and International Prostate Symptom Score resolution after external-beam radiotherapy combined with pulsed dose rate brachytherapy for prostate cancer.
    Pieters BR; Rezaie E; Geijsen ED; Koedooder K; van der Grient JN; Blank LE; de Reijke TM; Koning CC
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):758-64. PubMed ID: 20800377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds.
    Sugawara A; Nakashima J; Kunieda E; Nagata H; Asakura H; Oya M; Shigematsu N
    Radiat Oncol; 2010 Sep; 5():86. PubMed ID: 20875137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of trospium chloride in brachytherapy-related detrusor overactivity.
    Bittner N; Merrick GS; Brammer S; Niehaus A; Wallner KE; Butler WM; Allen ZA; Galbreath RW
    Urology; 2008 Mar; 71(3):460-4. PubMed ID: 18342187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erectile function after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer.
    Liu R; Luo F; Zhang Z; Xu Y
    Clin Genitourin Cancer; 2013 Sep; 11(3):251-5. PubMed ID: 23375828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting the severity of acute urinary toxicity after brachytherapy with iodine-125 for localized prostate cancer.
    Takeda K; Jingu K; Koto M; Fujimoto K; Narazaki K; Kubozono M; Saito H; Yamada S; Mitsuduka K; Ishidoya S; Ariga H; Arai Y; Yamada S
    Tohoku J Exp Med; 2011 Jan; 223(1):55-60. PubMed ID: 21212603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S; Cesaretti J; Stone NN; Stock RG
    BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA; Stock RG; Cesaretti J; Stone NN
    J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.